利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.02 秒)

    Diphenyl imidazoles as potassium channel modulators
    1.
    发明授权
    Diphenyl imidazoles as potassium channel modulators 有权
    二苯基咪唑作为钾通道调节剂

    公开(公告)号：US06271249B1

    公开(公告)日：2001-08-07

    申请号：US09538520

    申请日：2000-03-29

    申请人： Jeffrey L. Romine ,  Scott W. Martin ,  Piyasena Hewawasam ,  Nicholas A. Meanwell ,  Valentin K. Gribkoff ,  John E. Starrett, Jr.

    发明人： Jeffrey L. Romine ,  Scott W. Martin ,  Piyasena Hewawasam ,  Nicholas A. Meanwell ,  Valentin K. Gribkoff ,  John E. Starrett, Jr.

    IPC分类号： A61K31402

    CPC分类号： C07D263/58 ,  C07D233/64 ,  C07D233/70 ,  C07D233/76 ,  C07D235/12 ,  C07D249/12 ,  C07D249/14 ,  C07D271/113 ,  C07D413/10

    摘要： Novel compounds of Formula 1 are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels: wherein “Het” is one of a select group of heterocyclic moieties; Z is independently for each occurrence selected from O or S; Ra, Rb and Rc each are independently selected from hydrogen, halogen, OH, CF3, NO2, or provided Rc is not hydrogen; and when Ra and Rb are hydrogen, Rc may be a heterocyclic moiety selected from the group consisting of imidazol-1-yl, morpholinomethyl, N-methylimidazol-2-yl, and pyridin-2-yl; Rd and Re each are independently selected from hydrogen, halogen, CF3, NO2 or imidazol-1-yl; m, n and p each are independently selected from an integer of 0 or 1; and Rf and Rg each are independently hydrogen; C1-4 alkyl; or Rf and Rg, taken together with the nitrogen atom to which they are attached, is a heterocyclic moiety selected from the group consisting of N-methylpiperazine, morpholine, thiomorpholine, N-benzylpiperazine and imidazolinone.

    摘要翻译： 式1的新型化合物可用于治疗对大电导钙激活钾通道的开放剂起反应的病症：其中“Het”是选择性杂环部分组之一; Z独立地选自O或S; R a，R b和R c各自独立地选自氢，卤素，OH，CF 3，NO 2，或提供的R c不是氢; 当R a和R b为氢时，R c可以是选自咪唑-1-基，吗啉代甲基，N-甲基咪唑-2-基和吡啶-2-基的杂环部分; Rd和Re各自独立地选自氢，卤素，CF 3，NO 2或咪唑-1-基; m，n和p各自独立地选自0或1的整数; Rf和Rg各自独立地为氢; C 1-4烷基 或R f和R g与它们所连接的氮原子一起是选自N-甲基哌嗪，吗啉，硫代吗啉，N-苄基哌嗪和咪唑啉酮的杂环部分。

    3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
    6.
    发明授权
    3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease 有权
    KCNQ钾通道的3-氟-2-羟吲哚调节剂及其在治疗偏头痛和机械相关疾病中的应用

    公开(公告)号：US06855829B2

    公开(公告)日：2005-02-15

    申请号：US10075703

    申请日：2002-02-14

    申请人： Steven I. Dworetzky ,  Valentin K. Gribkoff ,  Gene G. Kinney ,  Piyasena Hewawasam

    发明人： Steven I. Dworetzky ,  Valentin K. Gribkoff ,  Gene G. Kinney ,  Piyasena Hewawasam

    IPC分类号： G01N33/50 ,  A61K31/404 ,  A61K31/506 ,  A61K45/00 ,  A61P25/06 ,  G01N33/15 ,  C07D209/34

    CPC分类号： A61K31/404 ,  A61K31/506

    摘要： Compounds which function as modulators, particularly, openers, of human KCNQ potassium channel proteins or polypeptides, particularly, central nervous system (CNS)-located KCNQ potassium channels, and heteromultimers thereof, and their use in the treatment of migraine are provided by the present invention. One novel type of potassium channel polypeptide openers provided by the present invention is the fluorooxindole compounds, described for the first time as therapeutics for the treatment of migraine by preventing the asynchronous firing of neurons. Other KCNQ potassium channel opener compounds that are also useful in the treatments of the invention include 2,4-disubstituted pyrimidine-5-carboxamide derivatives. One or more of the compounds according to the present invention may be utilized alone, in combination, or in conjunction with other treatment modalities for reducing, ameliorating and/or alleviating migraine or diseases similar to, or mechanistically related to, migraine, e.g., cluster headache.

    摘要翻译： 作为人KCNQ钾通道蛋白或多肽，特别是中枢神经系统（CNS）分配的KCNQ钾通道及其异源多肽的调节剂，特别是开放剂的化合物及其在治疗偏头痛中的用途由本发明提供 发明。 本发明提供的一种新型的钾通道多肽开放剂是氟氧吲哚化合物，首次作为通过防止神经元的异步烧制来治疗偏头痛的治疗剂。 也可用于本发明处理的其它KCNQ钾通道开放剂化合物包括2,4-二取代的嘧啶-5-甲酰胺衍生物。 根据本发明的一种或多种化合物可以单独使用，或与其它治疗方式联用，用于减少，改善和/或减轻与偏头痛相似或机械相关的偏头痛或类似疾病，例如，集群 头痛。

    Fluoro oxindole derivatives as modulators if KCNQ potassium channels
    7.
    发明授权
    Fluoro oxindole derivatives as modulators if KCNQ potassium channels 有权
    氟羟吲哚衍生物作为KCNQ钾通道的调节剂

    公开(公告)号：US06469042B1

    公开(公告)日：2002-10-22

    申请号：US10075522

    申请日：2002-02-14

    申请人： Piyasena Hewawasam ,  Pierre Dextraze ,  Valentin K. Gribkoff ,  Gene G. Kinney ,  Steven I. Dworetzky

    发明人： Piyasena Hewawasam ,  Pierre Dextraze ,  Valentin K. Gribkoff ,  Gene G. Kinney ,  Steven I. Dworetzky

    IPC分类号： A61K3405

    CPC分类号： C07D209/34

    摘要： There is provided novel 3-fluoro-3-phenyl oxindole derivatives of Formula I wherein R1, R2, R3 and R4 each are independently hydrogen, C1-4 alkyl, halogen, fluoromethyl, trifluoromethyl, phenyl, 4-methylphenyl or 4-trifluoromethylphenyl; R5 is C1-6 alkyl optionally substituted with one to three same or different groups selected from fluoro and chloro, provided R5 is not C1-6 alkyl when Y is O; Y is O or S; and R6 and R7 each are independently hydrogen, chloro, bromo or trifluoromethy; which are openers of the KCNQ potassium channels and are useful in the treatment of disorders which are responsive to the opening of the KCNQ potassium channels.

    摘要翻译： 提供式I的新型3-氟-3-苯基羟吲哚衍生物，其中R1，R2，R3和R4各自独立地为氢，C1-4烷基，卤素，氟甲基，三氟甲基，苯基，4-甲基苯基或4-三氟甲基苯基; R5为 任选被一至三个选自氟和氯的相同或不同的基团取代的C 1-6烷基，当Y是O时，R 5不是C 1-6烷基; Y是O或S; 和R6和R7各自独立地是氢，氯，溴或三氟甲基;它们是KCNQ钾通道的开放剂，并且可用于治疗响应于KCNQ钾通道开放的病症。

    Human KCNQ5 potassium channel, methods and compositions thereof
    10.
    发明申请
    Human KCNQ5 potassium channel, methods and compositions thereof 审中-公开
    人KCNQ5钾通道，其方法和组合物

    公开(公告)号：US20090005304A1

    公开(公告)日：2009-01-01

    申请号：US11824458

    申请日：2007-06-28

    申请人： Steven I. Dworetzky ,  Chandra S. Ramanathan ,  Joanne T. Trojnacki ,  Christopher G. Boissard ,  Valentin K. Gribkoff

    发明人： Steven I. Dworetzky ,  Chandra S. Ramanathan ,  Joanne T. Trojnacki ,  Christopher G. Boissard ,  Valentin K. Gribkoff

    IPC分类号： A61K38/00 ,  C07K14/00 ,  A61P43/00

    CPC分类号： C07K14/705 ,  A61K38/00 ,  C07K2319/00

    摘要： An isolated polynucleotide encoding a novel potassium channel polypeptide, KCNQ5, that is expressed primarily in brain and skeletal muscle is described. The new polypeptide has been cloned and isolated from a human brain cDNA library and is a member the KCNQ family of potassium channels. The provided human KCNQ5 nucleic acid sequence and encoded polypeptide can be employed for diagnostic, screening and therapeutic uses. Moreover, the hKCNQ5 polypeptide can be used to assay for KCNQ5 potassium channel modulators, which can be utilized in the treatment of neurological, neurophysiological, neuropsychological and neuroaffective diseases, conditions and disorders, including, but not limited to, acute and chronic pain, migraine, acute stroke, dementia, vascular dementia, trauma, epilepsy, amyelotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's Disease, learning and cognitive disorders, and neurophysiological disorders including anxiety disorders, depression, bipolar disorders, sleep disorders, addiction, and eating disorders.

    摘要翻译： 描述了编码主要在脑和骨骼肌中表达的新型钾通道多肽KCNQ5的分离的多核苷酸。 新的多肽已经从人脑cDNA文库克隆和分离，并且是钾通道KCNQ家族的成员。 提供的人类KCNQ5核酸序列和编码的多肽可用于诊断，筛选和治疗用途。 此外，hKCNQ5多肽可用于测定KCNQ5钾通道调节剂，其可用于治疗神经，神经生理学，神经心理学和神经感染性疾病，病症和障碍，包括但不限于急性和慢性疼痛，偏头痛 ，急性中风，痴呆，血管性痴呆，创伤，癫痫，青光眼性侧索硬化（ALS），多发性硬化症（MS），帕金森病，学习和认知障碍以及神经生理学障碍，包括焦虑症，抑郁症，双相情感障碍，睡眠障碍，成瘾 和饮食失调。